Terbinafine headache

Terbinafine Inhibits epoxidation of squalene in fungi increased levels are toxic to them Reduces ergosterol prevents synthesis of fungal cell membrane Mucocutaneous fungal infections Oral t duration, days Toxicity Gastrointestinal upset, headache, hepatoxicity t Interactions None reported... 

One tablet given daily for 12 weeks achieves a cure rate of up to 90% for onychomycosis and is more effective than griseofulvin or itraconazole. Adverse effects are rare, consisting primarily of gastrointestinal upset and headache. Terbinafine does not seem to affect the P450 system and has demonstrated no significant drug interactions to date. 

Terbinafine interferes with ergosterol biosynthesis, and thereby with the formation of the fungal cell membrane. It is absorbed from the gastrointestinal tract and undergoes extensive metabolism in the liver (tj 14 h). Terbinafine is used topically for dermatophyte infections of the skin and orally for infections of hair and nails where the site (e.g. hair), severity or extent of the infection render topical use inappropriate (see p. 315). Treatment (250 mg/d) may need to continue for several weeks. It may cause nausea, diarrhoea, dyspepsia, abdominal pain, headaches and cutaneous reactions. 

Terbinafine is usually well tolerated. Gastrointestinal complaints (dyspepsia, nausea, diarrhea) were the most common reasons for withdrawal. Abdominal pain and loss of taste were reported, as well as mild nervous system symptoms (headache and dizziness) (23). 

Headache, thrush, peripheral neuritis, phototoxicity ° Potentiates ethanol ° Avoid with history of porphyria Terbinafine... 

Clinical uses and toxicity Like griseofulvin, terbinafine accumulates in keratin, but it is much more effective than griseofulvin in onychomycosis. Adverse effects include gastrointestinal upsets, rash, headache, and taste disturbances. Terbinafine does not inhibit cytochrome P450. 

---